Peak Asset Management LLC Acquires New Position in Bristol Myers Squibb Company $BMY

Peak Asset Management LLC bought a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY) in the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 32,175 shares of the biopharmaceutical company’s stock, valued at approximately $1,854,000.

Other institutional investors also recently added to or reduced their stakes in the company. Northwestern Mutual Investment Management Company LLC grew its position in Bristol Myers Squibb by 0.3% in the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 65,046 shares of the biopharmaceutical company’s stock worth $3,509,000 after buying an additional 172 shares during the last quarter. KCM Investment Advisors LLC boosted its holdings in Bristol Myers Squibb by 0.8% in the fourth quarter. KCM Investment Advisors LLC now owns 20,871 shares of the biopharmaceutical company’s stock worth $1,126,000 after purchasing an additional 174 shares in the last quarter. Sandy Cove Advisors LLC increased its position in Bristol Myers Squibb by 4.7% during the second quarter. Sandy Cove Advisors LLC now owns 3,932 shares of the biopharmaceutical company’s stock worth $227,000 after buying an additional 176 shares during the last quarter. Investment Research Partners LLC raised its holdings in Bristol Myers Squibb by 1.4% during the fourth quarter. Investment Research Partners LLC now owns 13,134 shares of the biopharmaceutical company’s stock valued at $708,000 after buying an additional 179 shares in the last quarter. Finally, ESG Planning DBA Harper Investing lifted its position in shares of Bristol Myers Squibb by 1.3% in the fourth quarter. ESG Planning DBA Harper Investing now owns 13,811 shares of the biopharmaceutical company’s stock worth $745,000 after buying an additional 180 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Up 0.4%

Shares of NYSE:BMY opened at $67.30 on Tuesday. The company has a 50 day moving average price of $60.77 and a two-hundred day moving average price of $59.47. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The company has a market capitalization of $137.47 billion, a PE ratio of 14.82, a PEG ratio of 0.17 and a beta of 0.22. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.64.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. During the same quarter in the previous year, the business earned $1.46 EPS. The firm’s revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Analysts forecast that Bristol Myers Squibb Company will post 6.95 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were issued a dividend of $0.63 per share. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.7%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.51%.

Analysts Set New Price Targets

BMY has been the subject of several research reports. Guggenheim reissued a “buy” rating and issued a $75.00 price objective (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Raymond James Financial began coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a “strong-buy” rating on the stock. Bank of America reduced their price objective on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a research note on Friday, July 10th. Roth Capital started coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a “buy” rating and a $75.00 price target on the stock. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $59.00 price objective (up from $54.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $66.06.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.